.

Deeper Knowledge, Faster

  • Analyze global market entry opportunities
  • Identify first generic entrants
  • Set up watchlists for daily email updates

► See Plans & Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving 500+ biopharmaceutical companies globally:

Accenture
UBS
McKinsey
Dow
Merck
Cantor Fitzgerald
Novartis
Fuji
Medtronic
Deloitte

Generated: July 23, 2017

DrugPatentWatch Database Preview

NEVIRAPINE Drug Profile

« Back to Dashboard

Which patents cover Nevirapine, and what generic Nevirapine alternatives are available?

Nevirapine is a drug marketed by Aurobindo, Sandoz Inc, Aurobindo Pharma Ltd, Alvogen Malta, Apotex Inc, Mylan Pharms Inc, Prinston Inc, Cipla Ltd, Cipla, Mylan Labs, Sciegen Pharms Inc, Micro Labs Ltd, Hetero Labs Ltd Iii, and Strides Pharma. and is included in nineteen NDAs.

The generic ingredient in NEVIRAPINE is nevirapine. There are twenty drug master file entries for this compound. Nineteen suppliers are listed for this compound. There are seven tentative approvals for this compound. Additional details are available on the nevirapine profile page.

Summary for Tradename: NEVIRAPINE

Patents:0
Applicants:14
NDAs:19
Suppliers / Packagers: see list15
Bulk Api Vendors: see list77
Clinical Trials: see list199
Patent Applications: see list5,573
Formulation / Manufacturing:see details
Drug Prices:see details
DailyMed Link:NEVIRAPINE at DailyMed
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Aurobindo
NEVIRAPINE
nevirapine
SUSPENSION;ORAL077702-001May 22, 2012AARXNoNo► Subscribe► Subscribe
Hetero Labs Ltd Iii
NEVIRAPINE
nevirapine
TABLET;ORAL078584-001May 22, 2012ABRXNoNo► Subscribe► Subscribe
Aurobindo
NEVIRAPINE
nevirapine
TABLET;ORAL077521-001May 22, 2012ABRXNoNo► Subscribe► Subscribe
Alvogen Malta
NEVIRAPINE
nevirapine
TABLET, EXTENDED RELEASE;ORAL204621-002Nov 9, 2015ABRXNoNo► Subscribe► Subscribe
Cipla
NEVIRAPINE
nevirapine
TABLET;ORAL077956-001May 22, 2012ABRXNoNo► Subscribe► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Serving 500+ biopharmaceutical companies globally:

US Army
Covington
Harvard Business School
Merck
US Department of Justice
Moodys
Chubb
Dow
Chinese Patent Office
Medtronic

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted Heap | Mobile and Web Analytics

Follow DrugPatentWatch:



Google
Twitter
Google Plus
botpot